MRKR

Marker Therapeut

• TipRanks·5h ago

  Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), AbbVie (ABBV) and Marker Therapeutics (MRKR)

• NASDAQ·1d ago

  Marker Therapeutics Secures $2.6 Mln FDA Grant To Support Phase 1 Of Pancreatic Cancer Study

• TipRanks·1d ago

  Marker Therapeutics awarded $2.6M FDA Orphan Products development grant

• Benzinga·1d ago

  Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer

• Benzinga·3d ago

  12 Health Care Stocks Moving In Friday's Intraday Session

• NASDAQ·4d ago

  New Strong Buy Stocks for October 16th

• NASDAQ·09/22 16:45

  Marker Highlights Expanded Manufacturing Support For MT-601

• TipRanks·09/22 12:20

  Marker Therapeutics highlights expanded manufacturing support of CDMO partner

• TipRanks·09/22 10:20

  Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Milestone Pharmaceuticals (MIST) and Pfizer (PFE)

• Benzinga·08/25 21:06

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• TipRanks·08/20 12:50

  Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)

• TipRanks·08/17 12:19

  Marker Therapeutics: Buy Rating Reaffirmed as Pipeline Advances and Cash Runway Extends, Price Target Maintained at $8

• TipRanks·08/13 12:40

  Analysts’ Top Healthcare Picks: OrthoPediatrics (KIDS), Perrigo Company (PRGO)

• TipRanks·07/09 16:00

  Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)

• TipRanks·06/30 11:25

  Marker Therapeutics: Buy Rating Reaffirmed with Unchanged $8 Price Target on Optimism for MT-601 Data and Pivotal Pathway